Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
Public ClinicalTrials.gov record NCT01597193. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A PHASE 1 OPEN-LABEL, DOSE ESCALATION STUDY EVALUATING THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ENZALUTAMIDE (FORMERLY MDV3100) IN PATIENTS WITH INCURABLE BREAST CANCER
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine the safety, tolerability and pharmacokinetics of enzalutamide alone and in combination with anastrozole, or exemestane, or fulvestrant in patients with incurable breast cancer.
Study identification
- NCT ID
- NCT01597193
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 101 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2012 (Actual)
- Primary completion
- Dec 15, 2015 (Actual)
- Completion
- Jan 22, 2018 (Actual)
- Last update posted
- May 8, 2019
2012 – 2018
United States locations
- U.S. sites
- 17
- U.S. states
- 7
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| ATTN-Research Pharmacist | Aurora | Colorado | 80045 | — |
| University of Colorado Cancer Center | Aurora | Colorado | 80045 | — |
| University of Colorado Hospital, Anschutz Outpatient Pavilion | Aurora | Colorado | 80045 | — |
| Connecticut Multispecialty Group | Enfield | Connecticut | 06082 | — |
| Florida Cancer Specialists | Sarasota | Florida | 34232 | — |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| The West Clinic, PC | Corinth | Mississippi | 38834 | — |
| The West Clinic | Southaven | Mississippi | 38671 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10022 | — |
| Memorial Sloan Kettering Cancer Center - IDS Pharmacy | New York | New York | 10065 | — |
| Memorial Sloan Kettering Cancer Center - OPD Pharmacy | New York | New York | 10065 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| The West Clinic | Germantown | Tennessee | 38138 | — |
| The West Clinic | Memphis | Tennessee | 38104 | — |
| The West Clinic | Memphis | Tennessee | 38120 | — |
| Tennessee Oncology, PLLC. | Nashville | Tennessee | 37203 | — |
| The Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01597193, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 8, 2019 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01597193 live on ClinicalTrials.gov.